Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin

References

• International Diabetes FederationIDF Diabetes Atlas5th edn 2012 UpdateBrussels, BelgiumInternational Diabetes Federation2012
   Google Scholar
• National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011Atlanta, GAUS Department of Health and Human Services, Centers for Disease Control and Prevention2011
   Google Scholar
• StamlerJVaccaroONeatonJDWentworthDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care1993164344448432214
   PubMed Web of Science ®Google Scholar
• StevensRJKothariVAdlerAIStrattonIMThe UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)Clin Sci (Lond)200110167167911724655
   PubMed Web of Science ®Google Scholar
• TurnerRCMillnsHNeilHARisk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)BMJ19983168238289549452
   PubMed Web of Science ®Google Scholar
• BrunzellJDDavidsonMFurbergCDLipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology FoundationJ Am Coll Cardiol2008511512152418402913
   PubMed Web of Science ®Google Scholar
• AnberVGriffinBAMcConnellMPackardCJShepherdJInfluence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycansAtherosclerosis19961242612718830938
   PubMed Web of Science ®Google Scholar
• NigonFLesnikPRouisMChapmanMJDiscrete subspecies of human low density lipoproteins are heterogeneous in their interaction with the cellular LDL receptorJ Lipid Res199132174117531770294
   PubMed Web of Science ®Google Scholar
• TribbleDLHollLGWoodPDKraussRMVariations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle sizeAtherosclerosis1992931891991590824
   PubMed Web of Science ®Google Scholar
• GrundySMAtherogenic dyslipidemia associated with metabolic syndrome and insulin resistanceClin Cornerstone20068Suppl 1S21S2716903166
   PubMedGoogle Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculation20021063143342112485966
   PubMed Web of Science ®Google Scholar
• CatapanoALReinerZDe BackerGESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)Atherosclerosis201121734621882396
   PubMed Web of Science ®Google Scholar
• GenestJMcPhersonRFrohlichJ2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult – 2009 recommendationsCan J Cardiol20092556757919812802
   PubMed Web of Science ®Google Scholar
• AndersonTJGregoireJHegeleRA2012 update of the canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adultCan J Cardiol20132915116723351925
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes—2009Diabetes Care200932Suppl 1S13S6119118286
   PubMed Web of Science ®Google Scholar
• [No authors listed]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• CannonCPBraunwaldEMcCabeCHIntensive versus moderate lipid lowering with statins after acute coronary syndromesN Engl J Med20043501495150415007110
   PubMed Web of Science ®Google Scholar
• LaRosaJCGrundySMWatersDDIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med20053521425143515755765
   PubMed Web of Science ®Google Scholar
• BaigentCKeechAKearneyPMEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• KearneyPMBlackwellLCollinsREfficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysisLancet200837111712518191683
   PubMed Web of Science ®Google Scholar
• RydénLStandlEBartnikMTask Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC)European Association for the Study of Diabetes (EASD)Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD)Eur Heart J2007288813617220161
   PubMed Web of Science ®Google Scholar
• [No authors listed]The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research GroupN Engl J Med19933299779868366922
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ200032140541210938048
   PubMed Web of Science ®Google Scholar
• HoPMRumsfeldJSMasoudiFAEffect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitusArch Intern Med20061661836184117000939
   PubMed Web of Science ®Google Scholar
• CramerJAA systematic review of adherence with medications for diabetesDiabetes Care2004271218122415111553
   PubMed Web of Science ®Google Scholar
• YeawJBennerJSWaltJGSianSSmithDBComparing adherence and persistence across 6 chronic medication classesJ Manag Care Pharm20091572874019954264
   PubMed Web of Science ®Google Scholar
• PriestJLCantrellCRFinchamJCookCLBurchSPQuality of care associated with common chronic diseases in a 9-state Medicaid population utilizing claims data: an evaluation of medication and health care use and costsPopul Health Manag201114435421142926
   PubMed Web of Science ®Google Scholar
• BriesacherBAAndradeSEFouayziHChanKAComparison of drug adherence rates among patients with seven different medical conditionsPharmacotherapy20082843744318363527
   PubMed Web of Science ®Google Scholar
• ZhangQZhaoCDaviesMJRadicanLSeckTCompliance and persistence with concomitant statin and oral antihyperglycemic therapyAm J Manag Care20111774675222084894
   PubMed Web of Science ®Google Scholar
• PhillipsLSBranchWTCookCBClinical inertiaAnn Intern Med200113582583411694107
   PubMed Web of Science ®Google Scholar
• American Diabetes AssociationStandards of medical care in diabetes – 2011Diabetes Care201134Suppl 1S11S6121193625
   PubMed Web of Science ®Google Scholar
• MerzCNBuseJBTuncerDTwillmanGBPhysician attitudes and practices and patient awareness of the cardiovascular complications of diabetesJ Am Coll Cardiol2002401877188112446074
   PubMed Web of Science ®Google Scholar
• ChahilTJGinsbergHNDiabetic dyslipidemiaEndocrinol Metab Clin North Am200635491510viiviii16959582
   PubMed Web of Science ®Google Scholar
• KiortsisDNGiralPBruckertETurpinGFactors associated with low compliance with lipid-lowering drugs in hyperlipidemic patientsJ Clin Pharm Ther20002544545111123498
   PubMed Web of Science ®Google Scholar
• LaRosaJHLaRosaJCEnhancing drug compliance in lipid-lowering treatmentArch Fam Med200091169117511115225
   PubMedGoogle Scholar
• CheongCBarnerJCLawsonKAJohnsrudMTPatient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipientsClin Ther2008301893190719014846
   PubMed Web of Science ®Google Scholar
• PanFChernewMEFendrickAMImpact of fixed-dose combination drugs on adherence to prescription medicationsJ Gen Intern Med20082361161418288541
   PubMed Web of Science ®Google Scholar
• ThayerSArondekarBHarleyCDarkowTEAdherence to a fixed-dose combination of rosiglitazone/glimepiride in subjects switching from monotherapy or dual therapy with a thiazolidinedione and/or a sulfonylureaAnn Pharmacother20104479179920371759
   PubMed Web of Science ®Google Scholar
• DruckerDJNauckMAThe incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesLancet20063681696170517098089
   PubMed Web of Science ®Google Scholar
• HermanGASteinPPThornberryNAWagnerJADipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptinClin Pharmacol Ther20078176176717392725
   PubMed Web of Science ®Google Scholar
• Zocor (simvastatin) tablets [package insert]Whitehouse Station, NJMerck and Co, Inc2011
   Google Scholar
• PhamDQNogidAPlakogiannisRSitagliptin: a novel agent for the management of type 2 diabetes mellitusAm J Health Syst Pharm20086552153118319497
   PubMed Web of Science ®Google Scholar
• MauroVFClinical pharmacokinetics and practical applications of simvastatinClin Pharmacokinet1993241952028343198
   PubMed Web of Science ®Google Scholar
• CerraMLuoWLLiSXThe effects of simvastatin on the pharmacokinectics of sitagliptinJ Popul Ther Clin Pharmacol201219e356e36023077137
   PubMedGoogle Scholar
• BergmanAJCoteJMaesAEffect of sitagliptin on the pharmacokinetics of simvastatinJ Clin Pharmacol20094948348819204138
   PubMed Web of Science ®Google Scholar
• AschnerPKipnesMSLuncefordJKSanchezMMickelCWilliams-HermanDEEffect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetesDiabetes Care2006292632263717130196
   PubMed Web of Science ®Google Scholar
• BarzilaiNGuoHMahoneyEMEfficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trialCurr Med Res Opin2011271049105821428727
   PubMed Web of Science ®Google Scholar
• GoldsteinBJFeinglosMNLuncefordJKJohnsonJWilliams-HermanDEEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care2007301979198717485570
   PubMed Web of Science ®Google Scholar
• RazIHanefeldMXuLCariaCWilliams-HermanDKhatamiHEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitusDiabetologia2006492564257117001471
   PubMed Web of Science ®Google Scholar
• Williams-HermanDJohnsonJTengREfficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week studyCurr Med Res Opin20092556958319232032
   PubMed Web of Science ®Google Scholar
• Williams-HermanDJohnsonJTengREfficacy and safety of sitagliptin and metformin as initial combination therapy and as monotherapy over 2 years in patients with type 2 diabetesDiabetes Obes Metab20101244245120415693
   PubMed Web of Science ®Google Scholar
• AschnerPKatzeffHLGuoHEfficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetesDiabetes Obes Metab20101225226120070351
   PubMed Web of Science ®Google Scholar
• HanefeldMHermanGAWuMMickelCSanchezMSteinPPOnce-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetesCurr Med Res Opin2007231329133917559733
   PubMed Web of Science ®Google Scholar
• IwamotoYTaniguchiTNonakaKDose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitusEndocr J20105738339420332588
   PubMed Web of Science ®Google Scholar
• MohanVYangWSonHYEfficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and KoreaDiabetes Res Clin Pract20098310611619097665
   PubMed Web of Science ®Google Scholar
• NonakaKKakikawaTSatoAEfficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetesDiabetes Res Clin Pract20087929129817933414
   PubMed Web of Science ®Google Scholar
• NonakaKTsubouchiHOkuyamaKFukaoYJohnson-LevonasAOAmatrudaJMEffects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitusHorm Metab Res20094123223719253204
   PubMed Web of Science ®Google Scholar
• CharbonnelBKarasikALiuJWuMMeiningerGEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care2006292638264317130197
   PubMed Web of Science ®Google Scholar
• RazIChenYWuMEfficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetesCurr Med Res Opin20082453755018194595
   PubMed Web of Science ®Google Scholar
• ScottRLoeysTDaviesMJEngelSSEfficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetesDiabetes Obes Metab20081095996918201203
   PubMed Web of Science ®Google Scholar
• VilsbollTRosenstockJYki-JarvinenHEfficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetesDiabetes Obes Metab20101216717720092585
   PubMed Web of Science ®Google Scholar
• DobsASGoldsteinBJAschnerPEfficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized, placebo-controlled, 54-week trial in patients with type 2 diabetesJ Diabetes20135687922742523
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMLuoEFanurikDKhatamiHSteinPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab2007973374517593236
   PubMed Web of Science ®Google Scholar
• FonsecaVStaelsBMorganII JDEfficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetesJ Diabetes Complications20132717718323116881
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazgRAndryukPJLuKSteinPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther2006281556156817157112
   PubMed Web of Science ®Google Scholar
• SeckTNauckMShengDSafety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year studyInt J Clin Pract20106456257620456211
   PubMed Web of Science ®Google Scholar
• YoonKHShockeyGRTengREffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of beta-cell function in patients with type 2 diabetesInt J Clin Pract20116515416421235696
   PubMed Web of Science ®Google Scholar
• ReasnerCOlanskyLSeckTLThe effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitusDiabetes Obes Metab20111364465221410627
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• HaffnerSMAlexanderCMCookTJReduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival StudyArch Intern Med19991592661266710597756
   PubMed Web of Science ®Google Scholar
• CollinsRArmitageJParishSSleighPPetoRHeart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trialLancet20033612005201612814710
   PubMed Web of Science ®Google Scholar
• Williams-HermanDEngelSSRoundESafety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetesBMC Endocr Disord201010720412573
   PubMed Web of Science ®Google Scholar
• EscobarCEcharriRBarriosVRelative safety profiles of high dose statin regimensVasc Health Risk Manag2008452553318827903
   PubMedGoogle Scholar
• TalbertRLSafety issues with statin therapyJ Am Pharm Assoc (2003)20064647948816913392
   PubMed Web of Science ®Google Scholar
• ArmitageJThe safety of statins in clinical practiceLancet20073701781179017559928
   PubMed Web of Science ®Google Scholar
• [No authors listed]New simvastatin dosing recommendationsMed Lett Drugs Ther201153616221836544
   PubMed Web of Science ®Google Scholar
• BackesJMHowardPARuisingerJFMoriartyPMDoes simvastatin cause more myotoxicity compared with other statins?Ann Pharmacother2009432012202019920157
   PubMed Web of Science ®Google Scholar
• BaysHStatin safety: an overview and assessment of the data – 2005Am J Cardiol2006976C26C
   PubMed Web of Science ®Google Scholar
• RidkerPMPradhanAMacFadyenJGLibbyPGlynnRJCardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trialLancet201238056557122883507
   PubMed Web of Science ®Google Scholar
• SattarNPreissDMurrayHMStatins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trialsLancet201037573574220167359
   PubMed Web of Science ®Google Scholar
• Juvisync (sitagliptin and simvastatin) tablets [package insert]Whitehouse Station, NJMerck and Co, Inc2012
   Google Scholar
• FarrerMWinocourPHEvansKSimvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measuresDiabetes Res Clin Pract1994231111198070302
   PubMed Web of Science ®Google Scholar
• NewmanTBHulleySBCarcinogenicity of lipid-lowering drugsJAMA199627555608531288
   PubMed Web of Science ®Google Scholar
• FordIMurrayHPackardCJShepherdJMacfarlanePWCobbeSMLong-term follow-up of the West of Scotland Coronary Prevention StudyN Engl J Med20073571477148617928595
   PubMed Web of Science ®Google Scholar
• SeverPSChangCLGuptaAKWhitehouseAPoulterNRThe Anglo-Scandinavian Cardiac Outcomes Trial: 11-year mortality follow-up of the lipid-lowering arm in the UKEur Heart J2011322525253221873710
   PubMed Web of Science ®Google Scholar
• BlondeLWogenJKreilickCSeymourAAGreater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co-administered with metforminDiabetes Obes Metab2003542443114617228
   PubMed Web of Science ®Google Scholar